Impact Biomedical (IBO) Current Assets (2022 - 2026)
Impact Biomedical's (IBO) quarterly Current Assets came in at $377000.0 in Q1 2026, down 82.73% YoY from $2.2 million in Q1 2025, and down 8.27% on a QoQ basis from $411000.0 in Q4 2025.
Impact Biomedical (IBO) Current Assets (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Current Assets data on file, last reported at $377000.0 in Q1 2026.
- Quarterly Current Assets fell 82.73% year-over-year to $377000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $377000.0 (down 82.73% YoY) and the FY2025 annual result came in at $411000.0, down 83.21% from the prior year.
- Current Assets declined to $377000.0 in Q1 2026, from $411000.0 in the prior quarter.
- In the past five years, Current Assets ranged from a high of $3.2 million in Q3 2024 to a low of $122000.0 in Q4 2022.
- A 5-year average of $995153.8 and a median of $411000.0 in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets surged 637.35% — and 2025, when it sank 83.21%.
- Tracing IBO's Current Assets over 5 years: stood at $122000.0 in 2022, then jumped by 172.13% to $332000.0 in 2023, then surged by 637.35% to $2.4 million in 2024, then slumped by 83.21% to $411000.0 in 2025, then dropped by 8.27% to $377000.0 in 2026.
- The last three Current Assets figures came in at $377000.0 (Q1 2026), $411000.0 (Q4 2025), and $917000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 320,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 320,000.00 |
| Mar 31, 2026 | 377,000.00 |
| Dec 31, 2025 | 411,000.00 |
| Sep 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 2.18 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 307,000.00 |
| Mar 31, 2024 | 335,000.00 |
| Dec 31, 2023 | 332,000.00 |
| Sep 30, 2023 | 501,000.00 |
| Jun 30, 2023 | 348,000.00 |
| Dec 31, 2022 | 122,000.00 |